Patents
Literature
2 results about "Analeptic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An analeptic, in medicine, is a central nervous system stimulant. The term analeptic typically refers to respiratory analeptics (for example, doxapram). Analeptics are central nervous system stimulants that include a wide variety of medications used to treat depression, attention deficit hyperactivity disorder (ADHD), and respiratory depression. Analeptics can also be used as convulsants, with low doses causing patients to experience heightened awareness, restlessness and rapid breathing. The primary medical use of these drugs is as an anesthetic recovery tool or to treat emergency respiratory depression. Other drugs of this category are prethcamide, pentylenetetrazole, and nikethamide. Nikethamide is now withdrawn due to risk of convulsions. Analeptics have recently been used to better understand the treatment of a barbiturate overdose. Through the use of agents researchers were able to treat obtundation and respiratory depression.
Topical analgesic cream composition and method of preparation thereof
The present invention relates to a pharmaceutical topical analgesic cream composition comprising Mefenamic acid, counterirritants, soothing agent, oil or combination thereof and other pharmaceutically acceptable excipients. The present invention relates to the process for the preparation of pharmaceutical topical analgesic cream composition. Moreover, a topical analgesic cream composition is used in the management of pain in conditions such as osteoarthritis and rheumatoid arthritis.
Owner:BLUE CROSS LAB PVT LTD
Methods and compositions particularly for treatment of attention deficit disorder
PendingUS20260014087A1Organic active ingredientsNervous disorderImmediate releasePharmaceutical drug
There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
Owner:PURDUE PHARMA LP